Aduro Biotech

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Aduro Biotech sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,751 sponsors by registered trial count).

7 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Aduro Biotech: 7 sponsored US clinical trials, none currently recruiting.

Aduro Biotech sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer, with 1 trials.

Upper-quartile sponsor footprint

Aduro Biotech sits in the upper quartile of the sponsor corpus (#1,806 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

TERMINATED Phase 2

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

NCT03122548
TERMINATED Phase 2

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

NCT03175172
TERMINATED Phase 1

Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer

NCT03189030
TERMINATED Phase 1

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

NCT02575807
COMPLETED Phase 1

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

NCT01675765
COMPLETED Phase 2

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

NCT02004262
COMPLETED Phase 2

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

NCT01417000

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 4

Therapeutic Areas

2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer 1

How the Aduro Biotech early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 3 completed (43%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.